FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093257002> ?p ?o ?g. }

• W2093257002 endingPage "164" @default.
• W2093257002 startingPage "151" @default.
• W2093257002 abstract "Cancer is a multigenic disorder involving mutations of both tumor suppressor genes and oncogenes. A large body of preclinical data, however, has suggested that cancer growth can be arrested or reversed by treatment with gene transfer vectors that carry a single growth inhibitory or pro-apoptotic gene or a gene that can recruit immune responses against the tumor. Many of these gene transfer vectors are modified viruses that retain the capability of the virus for efficient gene delivery but are safer than the native virus due to modifications that eliminate or alter one or more essential viral functions. The field of viral-based gene transfer vectors for the treatment of cancer has now entered the final stage of clinical testing prior to possible product approvals. Three viral vectors are currently undergoing this Phase III or Phase II/III clinical testing for cancer treatment. All three of these vectors are based on adenovirus, a common human virus that in its native state can cause cold or flu-like symptoms. In two of these vectors, genes essential for viral replication have been replaced with the wild-type p53 tumor suppressor gene, a gene that is deleted or mutated in over 50% of human cancers and which, when transferred into tumor cells, can induce tumor cell death. The third vector retains more of the natural adenoviral functions and relies on replication in tumor cells to induce cell killing. These three vectors represent two of the approaches now being taken to develop viral-based gene transfer vectors for cancer treatment. Additional approaches include the transfer of genes capable of converting non-toxic prodrugs into toxic forms, using anti-angiogenic gene transfer to block the formation of tumor blood vessels, inhibiting the activity of oncogenes through blocks to transcription or translation, stimulating the body's own immune system with immunomodulatory genes, and cancer vaccination with genes for tumor antigens. The data derived to date from clinical trials with viral-based vector systems are promising. The vectors have been generally well-tolerated without the severe toxicities common to standard cancer treatments. Many of these vectors have been demonstrated to have anti-tumor activity in a clinical setting and to lead to tumor regressions or to reductions in the rate of tumor growth. Furthermore, the safety profile of these vector systems has allowed for their clinical testing in combination with conventional cancer treatments to determine their benefit in multi-modality therapy. As part of their clinical development, all three of the vectors in Phase III and Phase II/III clinical trials are being tested for their benefit in combination with chemotherapy in randomized trials. The field is also looking to future product opportunities with improvements that will further increase potency, safety, and/or ease of administration. These developments may expand the number of cells that are susceptible to infection or may target the vector to particular tumor types following an intravenous administration. Some of these approaches are already in clinical testing. Additional opportunities may utilize multigene strategies to target multiple pathways in cancer cells or expand the use of cytotoxic or cytostatic gene transfer in combination with immunotherapy." @default.
• W2093257002 created "2016-06-24" @default.
• W2093257002 creator A5048536262 @default.
• W2093257002 date "2002-06-01" @default.
• W2093257002 modified "2023-10-10" @default.
• W2093257002 title "Viral-Mediated Gene Transfer for Cancer Treatment" @default.
• W2093257002 doi "https://doi.org/10.2174/1389201023378445" @default.
• W2093257002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12022258" @default.
• W2093257002 hasPublicationYear "2002" @default.
• W2093257002 type Work @default.
• W2093257002 sameAs 2093257002 @default.
• W2093257002 citedByCount "58" @default.
• W2093257002 countsByYear W20932570022012 @default.
• W2093257002 countsByYear W20932570022014 @default.
• W2093257002 countsByYear W20932570022015 @default.
• W2093257002 countsByYear W20932570022016 @default.
• W2093257002 countsByYear W20932570022017 @default.
• W2093257002 countsByYear W20932570022018 @default.
• W2093257002 countsByYear W20932570022020 @default.
• W2093257002 countsByYear W20932570022021 @default.
• W2093257002 countsByYear W20932570022022 @default.
• W2093257002 crossrefType "journal-article" @default.
• W2093257002 hasAuthorship W2093257002A5048536262 @default.
• W2093257002 hasConcept C104317684 @default.
• W2093257002 hasConcept C111599444 @default.
• W2093257002 hasConcept C121608353 @default.
• W2093257002 hasConcept C140704245 @default.
• W2093257002 hasConcept C150194340 @default.
• W2093257002 hasConcept C159047783 @default.
• W2093257002 hasConcept C195286587 @default.
• W2093257002 hasConcept C2522874641 @default.
• W2093257002 hasConcept C2778264664 @default.
• W2093257002 hasConcept C32470452 @default.
• W2093257002 hasConcept C34981463 @default.
• W2093257002 hasConcept C40767141 @default.
• W2093257002 hasConcept C43953973 @default.
• W2093257002 hasConcept C502942594 @default.
• W2093257002 hasConcept C54355233 @default.
• W2093257002 hasConcept C555283112 @default.
• W2093257002 hasConcept C82210918 @default.
• W2093257002 hasConcept C86803240 @default.
• W2093257002 hasConcept C92087593 @default.
• W2093257002 hasConcept C96232424 @default.
• W2093257002 hasConceptScore W2093257002C104317684 @default.
• W2093257002 hasConceptScore W2093257002C111599444 @default.
• W2093257002 hasConceptScore W2093257002C121608353 @default.
• W2093257002 hasConceptScore W2093257002C140704245 @default.
• W2093257002 hasConceptScore W2093257002C150194340 @default.
• W2093257002 hasConceptScore W2093257002C159047783 @default.
• W2093257002 hasConceptScore W2093257002C195286587 @default.
• W2093257002 hasConceptScore W2093257002C2522874641 @default.
• W2093257002 hasConceptScore W2093257002C2778264664 @default.
• W2093257002 hasConceptScore W2093257002C32470452 @default.
• W2093257002 hasConceptScore W2093257002C34981463 @default.
• W2093257002 hasConceptScore W2093257002C40767141 @default.
• W2093257002 hasConceptScore W2093257002C43953973 @default.
• W2093257002 hasConceptScore W2093257002C502942594 @default.
• W2093257002 hasConceptScore W2093257002C54355233 @default.
• W2093257002 hasConceptScore W2093257002C555283112 @default.
• W2093257002 hasConceptScore W2093257002C82210918 @default.
• W2093257002 hasConceptScore W2093257002C86803240 @default.
• W2093257002 hasConceptScore W2093257002C92087593 @default.
• W2093257002 hasConceptScore W2093257002C96232424 @default.
• W2093257002 hasIssue "2" @default.
• W2093257002 hasLocation W20932570021 @default.
• W2093257002 hasLocation W20932570022 @default.
• W2093257002 hasOpenAccess W2093257002 @default.
• W2093257002 hasPrimaryLocation W20932570021 @default.
• W2093257002 hasRelatedWork W1540999517 @default.
• W2093257002 hasRelatedWork W2061025663 @default.
• W2093257002 hasRelatedWork W2113309441 @default.
• W2093257002 hasRelatedWork W2317428842 @default.
• W2093257002 hasRelatedWork W2333540146 @default.
• W2093257002 hasRelatedWork W2397990992 @default.
• W2093257002 hasRelatedWork W2405575630 @default.
• W2093257002 hasRelatedWork W2410565573 @default.
• W2093257002 hasRelatedWork W296627141 @default.
• W2093257002 hasRelatedWork W4220772236 @default.
• W2093257002 hasVolume "3" @default.
• W2093257002 isParatext "false" @default.
• W2093257002 isRetracted "false" @default.
• W2093257002 magId "2093257002" @default.
• W2093257002 workType "article" @default.